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cancer highlights the role of the EGFR variant III
and its clinical relevance
Kwang-Yu Chang1,2,4, Shan-Yin Tsai5, Shang-Hung Chen2,6, Hsiao-Hui Tsou3, Chia-Jui Yen4, Ko-Jiunn Liu2,
Hsun-Lang Fang7, Hung-Chang Wu8, Bin-Fay Chuang2, Shao-Wen Chou2, Careen K Tang10, Shyun-Yeu Liu9,11,
Pei-Jung Lu1, Ching-Yu Yen9,12* and Jang-Yang Chang2,4*Abstract
Background: Dysregulated epidermal growth factor receptor (EGFR)-phosphoinositide-3-kinase (PI3K)-AKT signaling
is considered pivotal for oral cancer, and the pathway is a potential candidate for therapeutic targeting.
Results: A total of 108 archival samples which were from surgically resected oral cancer were examined.
Immunohistochemical staining showed the protein expression of membranous wild-type EGFR and cytoplasmic
phosphorylated AKT was detected in 63.9% and 86.9% of the specimens, respectively. In 49.1% of the samples, no
phosphatase and tensin homolog (PTEN) expression was detected. With regard to the EGFR variant III (EGFRvIII),
75.0% of the samples showed positive expression for moderate to severe staining, 31.5% of which had high
expression levels. Real-time polymerase chain reaction assays for gene copy number assessment of PIK3CA revealed
that 24.8% of the samples had alterations, and of EGFR showed that 49.0% had amplification. Direct sequencing of
PIK3CA gene showed 2.3% of the samples had a hotspot point mutation. Statistical assessment showed the
expression of the EGFRvIII correlated with the T classification and TNM stage. The Kaplan-Meier analyses for patient
survival showed that the individual status of phosphorylated AKT and EGFRvIII led to significant differences in
survival outcome. The multivariate analysis indicated that phosphorylated AKT, EGFRvIII expression and disease
stage were patient survival determinants.
Conclusions: Aberrations in the EGFR-PI3K-AKT pathway were frequently found in oral cancers. EGFRvIII and
phosphorylated AKT were predictors for the patient survival and clinical outcome.
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Oral cancer (OC) is a subtype of head and neck cancer
(HNC) that arises from the oral cavity, and squamous
cell carcinoma is the most frequent histological type. In
2008, the worldwide estimated incidence was 263,900
cases, ranking 10th for male cancers [1]. In Taiwan, the
age-standardized incidence rate was 11.3 per 100,000 of
the male population [2]. Together with oropharynx and
hypopharynx diseases, HNC was the 4th most frequent* Correspondence: ycysmc@gmail.com; jychang@nhri.org.tw
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reproduction in any medium, provided the ormale cancer in Taiwan. The high incidence of HNC is a
consequence of prevalent betel nut consumption, which
is a major national health issue [3]. The substance is
harmful to the oral mucosa, leading to inflammation and
cell cycle alterations in normal keratinocytes that may
eventually contribute to tumorigenesis [4]. In fact, betel
quid has a higher tendency to induce oral leukoplakia
and submucosal fibrotic changes compared with other
habits, such as cigarette smoking and alcohol consump-
tion [5].
In contrast to traditional cytotoxic agents, evolving
modern oncology focuses on the intracellular signal
transduction pathways that are critical for cancer devel-
opment. One example is the epidermal growth factorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.jbiomedsci.com/content/20/1/43receptor (EGFR), a tyrosine kinase receptor located at
the cell membrane. Signals are transmitted through the
protein from extracellular ligands to intracellular mo-
lecular cascades [6]. Several studies have emphasized the
role of the EGFR in HNC, suggesting a dependence on
the elicited signal [7]. Based on this concept, a monoclo-
nal antibody, cetuximab, has been developed [8,9]. At
present, the successful introduction of the drug offers
treatment options for patients with late-stage HNC.
Following cetuximab, numerous novel specific inhibi-
tors currently under investigation are expected as thera-
peutic drugs in the future [10]. Nevertheless, a
successful preclinical study does not always ensure clin-
ical efficacy. To overcome such difficulties, it is funda-
mental to understand the molecular aberrations present
in cancer cells. It has been reported that in addition to
wild-type EGFR (EGFRwt), a truncated-form mutant,
type III variant (EGFRvIII), is also frequently observed
[11]. The mutant receptor distinguished to its wild-type
counterpart as missing of the extracellular domain 1 and
2, which is encoded by the segment in exon 2 to exon 7.
Lacking of these amino acids leads to structural acti-
vated conformation of the protein, showing constitu-
tively activation with preferred signaling through the
phosphoinositide-3-kinase (PI3K)-AKT pathway [12]. In
addition to the receptor tyrosine kinase, the oncogenic
cascade is oppositely regulated by intracellular factors to
activate AKT through phosphorylation, e.g. PI3K and
phosphatase and tensin homolog (PTEN). In fact, aber-
rations in these individual components often lead to
tumorigenesis, indicating their crucial roles in HNC
[11,13-16]. These investigations, however, have often
lacked analyses of the serial cascade members. It is
therefore worthwhile to undertake a global study of the
EGFR-PI3K-AKT pathway.
In this article, we focused on the regulatory factors of
the EGFR-PI3K-AKT pathway. The study used archived
clinical OC samples to determine the proportions of ab-
errant genes and proteins. The analyses further showed




All tumor materials used in this study were obtained
from the tissue bank of Chi-Mei Medical Center
Yongkang and Liouying branches. Under the regulatory
rules of the local ethics committees, the tumor samples
were collected for the tissue bank after the patient con-
sent forms were signed and completed. The samples
were de-identified before receipt; thus, no additional pa-
tient consent was required. The study protocol, which
included archival tissue procurement, was approved by
the Institutional Review Board from Chi-Mei MedicalCenter (IRB 10012-L05). Formalin-fixed paraffin-
embedded (FFPE) OC samples were then prepared. All
specimens were histologically confirmed to be squamous
cell carcinomas. The date of diagnosis was restricted to
prior to the year 2006, with the follow-up data up to
February 7, 2012. All patients received surgical resection
and other standard treatments following the guidelines
developed by the local head and neck cancer committee.
Clinical information including gender, age, stage [17],
tumor origin, and history of unhealthy habits was also
obtained.
Immunohistochemical (IHC) staining of tumor tissue
Antibodies for PTEN (138G8, #9559) and phosphorylated
AKT (pAKT, Ser 473, D9E, #4060) were purchased from
Cell Signaling Technology (Danvers, MA, USA), and the
wild-type EGFR antibody (EGFRwt, Novocastra™ RTU-
EGFR-384) was obtained from Leica Microsystems (Milton
Keynes, UK). The developed monoclonal antibody for
EGFRvIII (4-5H), which has been described previously, was
also used [18]. IHC staining was performed on 5-μm-thick
FFPE sections mounted on frosted slides. For pAKT, PTEN
and EGFRvIII, the tissues were first warmed at 60°C for 30
minutes. They were then deparaffinized in xylene, followed
by hydration with ethanol at concentrations from 100%,
95%, 85% to 75%. Next, the endogenous peroxidase was
quenched through incubation in hydrogen peroxide for 15
minutes. For antigen retrieval, the samples were treated with
autoclave boiling for 10 minutes in buffer. The sections were
then incubated with specific antibodies in diluent at 4°C
overnight. Next, a tag-staining procedure was applied to
label the targets using the EnVision + ® kit (Dako, Glostrup,
Denmark) according to the manufacturer’s protocol. For
EGFRwt staining, the procedures were performed with the
Bond-Max Automated IHC staining system (Leica
Biosystems Newcastle Ltd, Australia) following the manufac-
turer’s standard protocol with minimal modifications. The
slides were counterstained with hematoxylin.
Interpretation of the IHC staining results
The intensity and percentage of the markers for each
specimen were assessed by two independent patholo-
gists. The criterion for positive staining was defined as
more than 5% membranous staining for EGFRwt and
more than 5% cytoplasmic staining for pAKT and PTEN.
The percentage of EGFRvIII staining for each tumor
specimen was classified into five staining groups
according to the extent of moderate to strong cytoplas-
mic reactivity: 0, (none); 1+, (1 ~ 24%); 2+, (25 ~ 49%);
3+, (50 ~ 74%); and 4+, (75 ~ 100%).
DNA sequencing for PIK3CA mutation
The entire genomic DNA was extracted from FFPE tis-
sue using the Wizard® Genomic DNA Purification Kit
Table 1 Demography of patients characteristic (N = 108)
Factors N Factors N
Origin Age
Buccal 47 ≤30 2
Tongue 35 31-40 18
Gum 8 41-50 37
Lip 6 51-60 30
Palate 5 61-70 16
Retromolar trigone 4 ≥71 5
Mouth floor 3 Smoking
Gender Ever 86
Male 104 Never 18
Female 4 Unknown 4
T classification Alcohol
1 38 Ever 50
2 36 Never 50
3 6 Unknown 8
4 28 Betel nut
N classification Ever 78
0 72 Never 22
1 15 Unknown 8
2 21 Radiation
3 0 Received 66
TNM staging Not received 33
1 30 Unknown 9
2 24 Chemotherapy
3 13 Received 52
4 41 Not received 46
Unknown 10
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turer’s protocol. PIK3CA, which encodes the catalytic
subunit of class 1 PI3K, was highlighted because mis-
sense mutations are often found in cancer at G1624,
G1633 in exon 9 and A3140 in exon 20 [19]. Mutations
in these two exons which located in the helical domain
and the kinase domain, respectively, led to an increased
lipid kinase activity. For detection, specific primers for
PIK3CA were added to the DNA for use with a PCR kit
(Viogene, Taipei, Taiwan); the primers included the fol-
lowing sequences: exon 9 forward, 5-ccagaggggaaaa
atatgaca-3, reverse, 5-cattttagcacttacctgtgac-3; and exon
20 forward, 5-catttgctccaaactgacca-3, reverse, 5-
tgagctttcattttctcagttatcttttc-3 [20]. The amplified product
was then sequenced for hotspot mutations using ABI
Prism 3730 with the forward primers or the reverse
primers, if necessary.
Analysis of PIK3CA and EGFR copy numbers
The FAM™-labeled probes and the primers for PIK3CA
and EGFR were purchased from Applied Biosystems
(Foster City, CA, USA). The sequences used for gene
copy analysis of EGFR were as follows: forward primer,
5-actggaaaaaactgtttgggacct-3; reverse primer, 5-agctgttttc
acctctgttgcttat-3; and probe, 5-ccggtcagaaaacca-3 [21].
The primers and probe for the PIK3CA exon 20 were
designed using TaqMan® Copy Number Variation Assay
search tool on the Applied Biosystems website. The ma-
terials were then mixed with VIC® dye label-based RNase
P for reference gene detection, the genomic DNA ex-
traction and the Genotyping Master Mix (Applied
Biosystems). Mononuclear cells from healthy donors
were used for data normalization. For analysis, PCR was
performed using the Applied Biosystems 7500 Fast Real-
Time PCR System, and the cycle threshold (Ct) was cal-
culated. Copy number was assessed using the 2-ΔΔCt
method [22], with the normal gene copy number (GCN)
set as 2. The cutoff point for amplification was set as 3
instead of 4 because of the unavoidable interference
from nearby non-tumor tissue [23].
Statistical analyses
All data analyses were calculated using SPSS 14.0 (SPSS
Inc., Chicago, IL, USA) or SAS software, version 9.1
(SAS Institute, Inc., Cary, NC, USA). Two-sided
P-values less than 0.05 were considered significant. The
associations between factors were evaluated using the
chi-squared test or Fisher’s exact test when sample sizes
were small. The sample endpoint was overall survival,
defined as period from the date of operation to the doc-
umented expired date. Kaplan-Meier survival analyses
were performed to compare the differences in overall
survival between subgroups using the log-rank test. Uni-
variate and multivariate analyses were performed toidentify the possible variables related to overall survival.
The hazard ratio (HR) and corresponding 95% confi-
dence interval (CI) on univariate and multivariate ana-
lyses were calculated using the Cox proportional hazard
model. Factors of interest with P-values less than 0.1
and biological factors with probable impact were consid-
ered to be potentially associated with survival. These fac-
tors were then explored through multivariate analyses
using Cox proportional hazards regression with a step-
wise selection method to assess significance [24].
Results
Oral cancer samples are prepared for analysis
Specimens from 108 patients were used; the demo-
graphic characteristics are listed in Table 1. In addition
to surgery, 61.1% and 48.1% of the patients also received
radiotherapy and chemotherapy, respectively. Up to
96.3% samples were from males. A total of 32.4% of the
samples originated from the tongue, and 43.5%
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each TNM stage is shown in Figure 1, with similar sam-
ple numbers in each group; however, there were rela-
tively fewer samples in stage 3. The mean age was 50.6
years; the age distribution was normal and had a peak at
the age group 41–50. Regarding patient habits, we found
that 79.6% of the patients were either current or ever
smokers and that 72.2% of the patients had experienced
betel nut chewing. A total of 46.3% of the patients had a
history of alcohol consumption. These data were typical
for OC in Taiwan.
Dysregulated expression of EGFRwt, EGFRvIII, PTEN, and
pAKT is frequently observed
IHC staining was performed to detect EGFR, EGFRvIII
and PTEN expression in all samples; however, one sam-
ple lacked pAKT staining due to an insufficient amount
of tumor specimen. Regarding the subcelluar distribu-
tion, the majority of the immunoreactive signal was ob-
served in the cytoplasm for EGFRvIII, PTEN and pAKT
(Figure 2A, 2B). In contrast, EGFRwt expression was
detected in both the membrane and the cytoplasm
(Figure 2B). Using the criteria described in the Methods
section, 49.1% of these specimens were negative for
PTEN expression, and 86.9% were positive for pAKT ex-
pression. With regard to EGFRwt, 63.9% of the samples
were positive for the membranous expression of the
wild-type protein [25]. Conversely, moderate to strong
levels of EGFRvIII staining were present in the cyto-
plasm of 75% of the samples. EGFRvIII staining was fur-
ther scored as 1+, 2+, 3+, and 4+ based on the area
extent, with 24.1%, 19.4%, 24.1%, and 7.4% of the sam-
ples in each category, respectively. In summary, theFigure 1 Survival curves according to TNM stage. Representative
Kaplan-Meier plots for overall survival based on the classification of
each stage. The vertical tick marks indicate censored data, including
patients who were alive at the final day or who were lost to
follow up.aberrant expression of the individual cascade members
was frequently observed.
EGFR amplification correlates with dysregulated protein
expression
We next investigated GCNs using real-time PCR. Of 104
successfully analyzed samples for EGFR, 51 exhibited
GCN amplification (49.0%; Figure 3A). Further investiga-
tion showed that of the 67 samples with EGFRwt expres-
sion, 39 had simultaneous EGFR GCN amplification.
This was in comparison to the 12 samples (of a total 37)
that had negative EGFRwt protein detection, demon-
strating the expected correlation between these two fac-
tors (P = 0.012; Figure 3B). In contrast, 26 of 105
samples (24.8%) displayed increased GCN for PIK3CA,
including the only one with amplification.
For PIK3CA sequencing studies, segmental sequencing
of the hotspot mutation site in exons 9 and 20 were suc-
cessfully examined in 98 and 87 samples, respectively.
Neither the G1624 nor the G1633 substitution was
detected. Nevertheless, there were two samples bearing
a point mutation at A3140, with one replaced by guan-
ine and the other by thymine. Base substitution resulted
in altered coding for arginine and leucine instead of his-
tidine at the 1047 location of the catalytic domain. In
conclusion, hotspot point mutations of PIK3CA only
accounted for 2.3% of the OC samples.
EGFRvIII expression correlates with tumor size and stage
We then evaluated the associations between EGFRvIII
and other factors by grouping EGFRvIII into high-
expression or negative/low-expression according to the
IHC scores of 3+ and 4+ (31.5%) or 0/1+ and 2+ (25%
negative, 43.5% low expression); Table 2). Within the
108 samples, 54 of them were recorded as stage 3/4 dis-
ease and 54 as stage 1/2 disease. High EGFRvIII expres-
sion levels were noted in 40.7% of stage 3/4 disease
cases and in 22.2% of stage 1/2 disease cases. A signifi-
cant association was observed between the expression of
the truncated protein and disease stage (P < 0.001). A
similar observation was noted for the T but not N classi-
fications (P < 0.001 and P = 0.071, respectively).
We next focused on the interactions among EGFRvIII
and other signaling pathway members. As shown in
Table 2, high EGFRvIII expression levels were detected
in 35.3% of the samples with EGFR GCN amplification
and in 31.9% of those with EGFRwt protein expression
(P = 0.529 and P = 1.000, respectively). In addition, 40.0%
of the 55 PTEN-positive samples showed high EGFRvIII
expression levels compared with 22.6% of the PTEN-
negative samples (P = 0.064). The result was also not sig-
nificant in PIK3CA. High expression of the variant pro-
tein was noted in 30.8% of the samples with increased
PIK3CA GCN, comparing to 32.9% of those which were
Figure 2 Immunohistochemical staining of the tumor tissue. (A) Negative EGFRvIII expression is shown on the left, grade 1 in the middle,
and grade 2–3 in the right panels. The significant cytoplasmic staining is shown at a higher resolution in the inset square. (B) Representative
EGFRwt, PTEN, and pAKT staining results are shown in the left, middle, and right columns, respectively. Examples of negative and positive
samples are shown in the upper and lower rows, respectively. A higher resolution of EGFRwt membranous staining is shown in the inset square.
Each digital image was directly captured to the computer using light microscopy at a resolution of 200 ×.
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of the mutant receptor were observed in 32.3% of the 93
pAKT-positive and 21.4% of the pAKT-negative speci-
mens (P = 0.543). The analyses showed nonsignificant re-
sults for the association of EGFRvIII status and other
biomarkers in the cascade.Figure 3 Gene copy numbers of the samples. (A) A scattergram of the
of the individual specimen analyzed using real-time PCR and the C-2Δtt met
than 3. Dots above the lower dashed line have copy number of more than
is shown by the bar chart. The empty and solid bars represent negative or
Chi-Square analysis.EGFRvIII and pAKT expression correlates with poor
patient prognosis
EGFR has been suggested to be a prognostic factor in
HNC [26,27]. In our analyses, classification by PTEN
status and EGFRwt protein expression and GCN were
insufficient to show survival differences with theirEGFR or PIK3CA results are shown. Each dot represents the specific GCN
hod. Dots above the upper dotted line have copy number of more
2. (B) An association study of EGFR expression and GCN amplification
positive GCN amplification. The P level was assessed through
Table 2 Association analyses of EGFRvIII expressing
status with the other factors
EGFRvIII expression
P-valueTotal Negative or low High
Staging
T classification# 108
1 38 35 3 <0.001
2 36 20 16
3 6 4 2
4 28 15 13
N classification 108
0 72 53 19 0.071
1 15 11 4
2 21 10 11
TNM stage 108
1 30 29 1 <0.001
2 24 13 11
3 13 10 3
4 41 22 19
Factors
EGFR GCN amplification 104
Negative 53 38 15 0.529
Positive 51 33 18
EGFR expression 108
Negative 39 27 12 1.000
Positive 69 47 22
PIK3CA GCN increase 105 1.000
Negative 79 53 26
Positive 26 18 8
PTEN expression 108
Negative 53 41 12 0.064
Positive 55 33 22
pAKT expression# 107
Negative 14 11 3 0.543
Positive 93 63 30
P-value was estimated using chi-square method or #Fisher’s exact test.
Figure 4 The impact of pAKT and EGFRvIII on patient survival.
A representative Kaplan-Meier plot for overall survival based on the
classification of (A) pAKT status, positive or negative, and (B) EGFRvIII
expression, negative/low or high. The vertical tick marks indicate
censored data, including patients who were alive at the final day or
who were lost to follow up.
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trast, the survival curves for patients with different
pAKT or EGFRvIII statuses showed significant differ-
ences (P = 0.042 and P = 0.001, respectively; Figure 4A
and 4B). We then studied the survival impact of multiple
parameters including age, sex, history of unhealthy
habits, and aberrant factors. The results of univariate
analyses indicated that stage 4 disease and EGFRvIII and
pAKT expression statuses were the applicable factors
(P < 0.001, P = 0.002 and P = 0.050, respectively; Table 3).
Both EGFRvIII and pAKT were then included in a step-
wise regression with age, TNM stage, and habits. Theresult revealed that in addition to the disease stage, the
expression levels of EGFRvIII and pAKT status were sig-
nificant factors for patient survival after adjustment (P =
0.007, P = 0.046, and P = 0.049, respectively).
Discussion
Understanding cancer biology is fundamental for specific
target selection in developing drugs for modern oncol-
ogy. Our study focused on the EGFR-PI3K cascade
in OC, which demonstrated a high frequency of
dysregulated factors. In addition to the frequently ob-
served EGFRwt and GCN variations, EGFRvIII and the
absence of PTEN were also notable. However, PIK3CA
gene aberrations were rare in OC. Together, the pathway
anomalies led to activated pAKT, which impacted pa-
tient survival. Moreover, our study reinforced the
Table 3 Univariate and multivariate analyses for the overall survival
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age# ≤30 NA§ NA§
31-40 1 (reference) 1 (reference)
41-50 0.88 (0.43–1.81) 0.721 0.64 (0.25–1.62) 0.343
51-60 0.67 (0.31–1.47) 0.318 0.83 (0.32–2.15) 0.705
61-70 1.17 (0.52–2.66) 0.704 0.96 (0.30–3.08) 0.949
≥71 0.51 (0.11–2.29) 0.376 0.52 (0.06–4.73) 0.564
Alcohol# No 1 (reference) 1 (reference)
Yes 1.03 (0.62–1.74) 0.899 1.07 (0.54–2.11) 0.842
Smoking# No 1 (reference) 1 (reference)
Yes 1.44 (0.71–2.93) 0.315 1.98 (0.79–4.97) 0.145
Betel nut# No 1 (reference) 1 (reference)
Yes 1.64 (0.83–3.26) 0.156 1.00 (0.42–2.37) 0.999
TNM staging# 1 1 (reference) 1 (reference)
2 1.18 (0.50–2.78) 0.703 0.76 (0.26–2.23) 0.618
3 2.35 (0.95–5.86) 0.066 2.16 (0.78–6.02) 0.140
4 4.21 (2.12–8.40) <0.001 3.53 (1.41–8.81) 0.007
EGFR Negative 1 (reference)
Positive 1.19 (0.70–2.02) 0.516 NA
EGFR GCN Non-amplified 1 (reference)
Amplified 0.94 (0.57–1.57) 0.822 NA
EGFRvIII# Low 1 (reference)
High 2.27 (1.36–3.79) 0.002 1.98 (1.01–3.87) 0.046
PTEN Negative 1 (reference)
Positive 1.26 (0.77–2.08) 0.359 NA
pAKT# Negative 1 (reference)
Positive 2.51 (1.00–6.27) 0.050 2.67 (1.01–7.07) 0.049
CI confidence interval, HR hazard ratio, NA not assessed.
#Factors included in multivariate analysis.
§Not assessed because the patient number was too small.
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ticular being the major contributory element that
influenced patient survival and outcome. To our know-
ledge, we are the first to report survival differences by
EGFRvIII classification in OC.
The truncated variant EGFRvIII draws attention to the
constitutive signaling activity, which is independent of
ligand binding [28]. The actual mechanism of the pro-
duction of this mutant receptor remains unknown. In a
HNC study conducted by Sok, et al., EGFRvIII was ex-
clusively expressed in coexistant with EGFRwt [11]. The
different observation in our study may therefore suggest
a distinguished feature specified to OC comparing to
other HNC diseases, or rather a unique feature in betel-
nut prevalent area. In fact, a breast cancer study has in-
dicated that EGFRvIII expression is not a consequence
of EGFR locus rearrangement or amplification but israther due to alterative splicing events [29]. This notion
was supported by our study and other brain tumor stud-
ies, as the appearance of EGFRvIII was not necessarily
co-existed or co-related with EGFRwt protein expression
or gene amplification [30,31]. In these cancer diseases,
the probable indispensable roles of the mutant protein
in tumorigenesis are therefore to be expected. Unlike in
brain tumors, in which the impact of EGFRvIII on sur-
vival is known [32-34], its function in OC and other
HNC are ambiguous, though frequently detected. In
addition to our study, previous studies have failed to
prove the determinant role of the truncated protein for
survival outcome [27,35]. This failure may be due to the
preceding reason and due to the different methods uti-
lized in the investigations. In fact, accurately detecting
the mutant protein is challenging because of interference
from EGFRwt and the nearby non-tumor tissue.
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used IHC staining because of its direct indication of the
signal distribution. In addition, IHC possesses a specifi-
city that is comparable to PCR over laser capture
microdissected tissue [36]. The application of this
method led us to demonstrate the crucial role of
EGFRvIII. This result was not unexpected because of the
association with disease stage, which has also been
shown by Keller and colleagues [37].
In our studies, we found that the major subcellular
distribution area of the variant protein was in the cyto-
plasm, whereas EGFRwt expression was detected at both
the membrane and in the cytoplasm. This result was
consistent with those observed in the human glioblast-
oma samples and in the breast cancer samples [36,38].
The definite causes leading to the distinct phenomenon
are not yet clear. It has been suggested that trivial differ-
ences in signaling and functioning distinguish EGFRvIII
and its wild-type counterpart. One possible example is
the defective downregulation of the truncated receptor
due to the hypophosphorylation of residue Y1045, lead-
ing to escape from ubiquitination by c-Cbl [39]. Another
example was the demonstration of a large intracellular
pool of EGFRvIII functioning with Src to reduce the glu-
cose dependency when relocalizing to the mitochondria
[40]. Taken together, these studies along with our data
support the role of cytoplasmic EGFRvIII in tumorigen-
esis. Therefore, further research to elucidate the mech-
anism of intracellular redistribution is imperative.
Though positive correlation was shown between the
EGFR expression and the GCN amplification, we found
that they were not completely overlapped. In recent re-
ports, discrepancies have been noted between these two
factors in OC [25,41]. The exact mechanisms in the
samples that had controversies within the two factors re-
main unclear. Regarding the protein producing process,
the accurate regulatory mechanism of transcription and
translation from the EGFR coding gene is not fully
understood. Complicated modulation against EGFR gene
transcription was noted, for example, that the regulation
mechanism depends on the length of a CA repeat in in-
tron 1 [42]. In addition, Wheeler and colleagues found
despite of correlation with EGFR gene amplification sta-
tus and the protein levels, the level of EGFR mRNA was
not associated to both factors [27]. This indicated post-
translational regulation was at least in part crucial to the
protein expression. Therefore, it was not surprising that
some samples have positive EGFR protein expression
without GCN amplification, and vice versa.
Recent investigations have emphasized the role of
PI3K in HNC [43]. Our study of the PIK3CA gene, how-
ever, indicated that GCN amplification or hotspot point
mutations were rare. This finding was in contrast to sev-
eral reports that highlighted the frequent aberrations ofthe gene itself. Examples of such reports include a study
that found that 34.8% of OC samples exhibit high GCN
amplifications [44] and another showing that 11% of
HNC samples carry hotspot point mutations [11].
Nevertheless, contradictory results were also noted in
the OC study conducted by Kozaki and colleagues [45].
In the 108 OC primary tumor samples analyzed, 16.7%
of those showed altered copy number for a 1.3 ~ 3.4-fold
increase, and four samples were detected of bearing
hotspot point mutations. Taken together with our study,
these data suggest that GCN variations of PIK3CA en-
coding areas were not as significant as EGFR alterations.
Finally, the possibility that the discrepancy in these ob-
servations is due to population differences should be fur-
ther examined.
The pAKT expression levels in our samples were high
and correlated with patient survival. As the preferred
signaling protein, it was unexpected that its associations
with EGFRvIII or EGFRwt (data not shown) expression
were not significant [46]. One reasonable potential ex-
planation is the interruption of the other regulatory fac-
tors as compensation. For instance, PTEN is known to
be a negative modulator of this pathway. Because AKT,
and likely STAT3 [47], are oppositely regulated by
EGFRvIII and PTEN, its activation was thus speculated
as a result of feedback reaction. In addition, further
studies have uncovered alternative routes that may be
responsible for tumorigenesis by the truncated protein,
such as through CXCR4 and cyclooxygenase-2 [48,49].
These proteins bypass the cascade, attenuating the de-
pendency of the AKT pathway without dispelling
EGFRvIII tumorigenic impact.
Conclusion
We demonstrated the indispensible roles of pAKT and
EGFRvIII in OC, which likely act as the determinant fac-
tors for patient survival. The data suggest that pAKT
and EGFRvIII could be used as prognostic markers, and
a validation of our findings is warranted. Although not
studied here, the fact that frequent aberrations in EGFR-
PI3K-AKT pathway lead to resistance to EGFR targeting
therapy should be further investigated in OC [11,50,51].
Finally, our results lead to the rationale for future clin-
ical investigations of the specific inhibitors that have
already shown benefit for tumor control [52,53].
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